Blood Screening Market Size, Share, Growth, and Industry Analysis, By Type (Reagent,Instrument), By Application (Blood Bank,Hospital), Regional Insights and Forecast to 2035

Blood Screening Market Overview

The global Blood Screening Market size is projected to grow from USD 3374.21 million in 2026 to USD 3623.9 million in 2027, reaching USD 6397.44 million by 2035, expanding at a CAGR of 7.4% during the forecast period.

The global Blood Screening Market is expanding rapidly due to the increasing need for accurate detection of transfusion-transmissible infections and advanced screening technologies. More than 118 million blood donations are collected worldwide annually, with approximately 75% undergoing advanced screening using nucleic acid testing (NAT) and enzyme-linked immunosorbent assay (ELISA). Automation in screening has improved throughput by 35%, enabling the testing of up to 300 samples per hour in modern laboratories. In 2024, over 62% of healthcare facilities globally adopted molecular diagnostic-based blood screening systems to detect HIV, Hepatitis B, Hepatitis C, and other infectious pathogens efficiently and with reduced human error.

The United States represents approximately 32% of the global Blood Screening Market, supported by strong blood donation programs and stringent FDA regulations. In 2024, over 16 million blood donations were collected across the U.S., with 99.9% undergoing advanced pathogen screening. About 65% of American blood banks utilize automated immunoassay analyzers, and 45% have transitioned to fully integrated NAT platforms for high-accuracy testing. The U.S. government’s increased focus on preventing transfusion-related infections has led to more than $500 million worth of modernization in public blood screening laboratories, resulting in 25% faster turnaround times and improved donor safety nationwide.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

Key Findings

• Key Market Driver: Approximately 68% of market growth is driven by the rising global prevalence of transfusion-transmissible diseases such as Hepatitis B, C, and HIV, with infection detection rates improving by 30% due to next-generation immunoassays and NAT technologies.
• Major Market Restraint: Nearly 35% of small healthcare facilities face challenges due to high reagent and equipment costs, with consumables accounting for 60% of total operational expenses in blood screening laboratories.
• Emerging Trends: Over 45% of screening laboratories are integrating artificial intelligence-based analysis and data management systems to enhance diagnostic accuracy and reduce false negatives by 25%.
• Regional Leadership: North America dominates the market with a 35% share, followed by Europe at 25%, and Asia-Pacific contributing 30% of global demand driven by expanding healthcare infrastructure.
• Competitive Landscape: The top five manufacturers—Abbott, Roche, Grifols, Bio-Rad Laboratories, and Beckman Coulter—account for 65% of global market share, driven by strong innovation pipelines and global distribution networks.
• Market Segmentation: Reagents contribute 58% of total market volume, while instruments hold 42%, reflecting increasing automation adoption in centralized laboratories and blood banks.
• Recent Development: Between 2023–2025, more than 25 advanced NAT systems and automated immunoassay analyzers were introduced, reducing testing time by 40% and enhancing throughput efficiency.

Blood Screening Market Latest Trends

The Blood Screening Market Trends indicate a global shift toward molecular-based and AI-assisted testing methodologies. The deployment of multiplex NAT systems capable of detecting multiple pathogens in a single test has increased by 38% in the past two years. Laboratories worldwide now process over 80 million blood samples annually using automated analyzers equipped with robotics, reducing manual intervention by 50%. AI and machine learning algorithms are being integrated into test result interpretation, improving diagnostic accuracy rates by 28%. Miniaturized microfluidic devices have made point-of-care blood screening more accessible, particularly in emerging economies, covering nearly 45% of rural healthcare centers. The Blood Screening Market Analysis also highlights a steady increase in demand for high-throughput equipment in hospital settings, with machines capable of handling 400–600 samples/hour. Screening of infectious diseases such as Zika, Dengue, and COVID-19 through multiplex PCR has risen by 20%, illustrating diversification in pathogen testing. Furthermore, automated data integration with electronic health records (EHR) systems has improved operational efficiency by 35%. Collectively, these trends demonstrate that innovation and automation remain the driving forces behind Blood Screening Market Growth and improved patient outcomes worldwide.

Blood Screening Market Dynamics

DRIVER

"Rising Prevalence of Transfusion-Transmissible Infections"

The primary driver of the Blood Screening Market Growth is the increasing incidence of transfusion-transmissible infections (TTIs) such as HIV, Hepatitis B, Hepatitis C, and Zika virus. Globally, 38 million people live with HIV, and 58 million have chronic Hepatitis C infections. The World Health Organization mandates that 100% of donated blood undergo standardized screening to minimize transmission risks. Automated NAT systems, adopted by 60% of major blood centers, enable simultaneous detection of up to 5 pathogens in a single run, increasing efficiency by 40%. Improved public health programs and government initiatives continue to strengthen this key growth driver.

RESTRAINT

"High Cost of Reagents and Instruments"

A major restraint on Blood Screening Market Expansion is the high cost associated with testing reagents and analyzers. Reagents typically account for 50–60% of total laboratory expenses, with prices increasing by 12–15% annually due to global supply chain disruptions. Smaller clinics, particularly in developing regions, struggle to invest in modern immunoassay analyzers costing between $20,000–$80,000. Additionally, advanced NAT testing kits range between $25–$50 per test, limiting affordability. Over 30% of regional laboratories in Africa and Southeast Asia still rely on manual serological methods, reflecting cost-driven disparities in technological adoption.

OPPORTUNITY

"Technological Integration and Automation"

Technological innovation represents a major opportunity for Blood Screening Market Growth. Automated systems now reduce hands-on technician time by 70%, while robotics-enabled sample handling boosts productivity by 50%. In 2024, over 75% of blood banks in developed nations transitioned to fully automated screening platforms capable of real-time result tracking. Digital integration with laboratory information systems (LIS) has improved traceability and quality control, reducing errors by 20%. Emerging markets such as India, China, and Brazil are witnessing rapid expansion in automation investment, with 150+ new facilities adopting AI-based testing modules. The shift toward decentralized, networked testing is expected to reshape global diagnostic workflows in the coming decade.

CHALLENGE

"Data Management and Quality Assurance"

Data accuracy and regulatory compliance pose ongoing challenges in the Blood Screening Market. Laboratories process millions of samples yearly, generating over 10 terabytes of data across multiple platforms. Managing this information securely and ensuring regulatory alignment with organizations such as the FDA and WHO requires advanced software solutions. Inconsistent data reporting leads to an estimated 8–10% of retests annually. Furthermore, maintaining reagent stability and calibration standards across different climates adds operational complexity. As laboratories scale up, ensuring consistent quality assurance across 500+ global facilities remains one of the key industry challenges.

Blood Screening Market Segmentation

Get Comprehensive Insights on the Market Segmentation in this Report

Download FREE Sample

BY TYPE

Reagents: Reagents account for 58% of the global Blood Screening Market Share, as they form the backbone of serological and molecular testing. More than 4 billion reagent-based tests are conducted annually. Modern enzyme and chemiluminescent reagents have improved detection sensitivity by 30% compared to traditional assays. Reagent kits for NAT screening are widely used for detecting Hepatitis and HIV in early infection stages, offering detection accuracy above 99.8%.

The Reagent segment is projected to reach USD 3,814.15 million by 2034, accounting for 64.0% of the total market share, expanding at a CAGR of 7.6%, driven by increasing use in blood donation centers and diagnostic laboratories for infectious disease screening.

Top 5 Major Dominant Countries in the Reagent Segment:

• United States: USD 975.32 million by 2034, 25.6% share, CAGR 7.5%, driven by high testing volumes and demand for advanced reagents in transfusion safety programs.
• China: USD 815.41 million by 2034, 21.4% share, CAGR 7.8%, supported by expanding blood donation programs and government-funded screening initiatives.
• Germany: USD 415.27 million by 2034, 10.8% share, CAGR 7.4%, fueled by growing focus on pathogen reduction and molecular diagnostics.
• Japan: USD 355.19 million by 2034, 9.3% share, CAGR 7.5%, attributed to high adoption of nucleic acid testing (NAT) technologies.
• India: USD 305.14 million by 2034, 8.0% share, CAGR 7.9%, boosted by improved healthcare infrastructure and increased awareness of transfusion safety.

Instruments: Instruments constitute 42% of the market, encompassing automated analyzers, NAT systems, and ELISA platforms. Globally, over 25,000 high-throughput analyzers are in operation, primarily across centralized blood centers. Instruments with modular designs process up to 600 tests/hour, enhancing throughput by 40%. Portable instruments for field blood collection centers are growing rapidly, particularly in Asia-Pacific, where affordability and efficiency drive adoption.

The Instrument segment is forecasted to reach USD 2,142.49 million by 2034, representing 36.0% of the market share, growing at a CAGR of 7.2%, due to technological advancements in automated analyzers and high-throughput screening systems.

Top 5 Major Dominant Countries in the Instrument Segment:

• United States: USD 625.37 million by 2034, 29.1% share, CAGR 7.1%, driven by adoption of next-generation blood analyzers and molecular testing platforms.
• China: USD 445.28 million by 2034, 20.8% share, CAGR 7.4%, influenced by automation in blood banks and screening facilities.
• Germany: USD 285.16 million by 2034, 13.3% share, CAGR 7.2%, supported by use of advanced immunoassay and PCR-based instruments.
• Japan: USD 245.19 million by 2034, 11.4% share, CAGR 7.3%, due to the modernization of blood testing laboratories.
• United Kingdom: USD 205.12 million by 2034, 9.6% share, CAGR 7.0%, propelled by rising demand for integrated diagnostic systems in healthcare facilities.

BY APPLICATION

Blood Banks: Blood banks hold 55% of the total Blood Screening Market Size. There are over 13,000 licensed blood banks worldwide, with more than 5,000 operating in Asia. Automated NAT systems are used in 65% of high-volume blood centers to test for multiple viruses simultaneously. Advanced storage and digital screening integration have reduced discard rates of contaminated blood by 12% globally. The adoption of fully automated screening in blood banks enhances traceability, donor data management, and screening accuracy.

The Blood Bank segment is anticipated to reach USD 3,745.11 million by 2034, capturing 62.9% share, with a CAGR of 7.5%, driven by stringent regulatory requirements and routine screening of donated blood to ensure transfusion safety.

Top 5 Major Dominant Countries in the Blood Bank Application:

• United States: USD 945.18 million by 2034, 25.2% share, CAGR 7.5%, supported by strong infrastructure for blood safety management.
• China: USD 805.21 million by 2034, 21.5% share, CAGR 7.7%, driven by government support for blood donation initiatives.
• Germany: USD 405.18 million by 2034, 10.8% share, CAGR 7.4%, fueled by advanced donor screening programs.
• Japan: USD 345.11 million by 2034, 9.2% share, CAGR 7.5%, influenced by increased reliance on NAT-based screening.
• India: USD 290.28 million by 2034, 7.7% share, CAGR 7.8%, supported by public awareness and safety compliance.

Hospitals: Hospitals represent 45% of the total market. More than 80% of hospitals globally conduct in-house screening for donor and patient safety. Integration of compact analyzers enables faster turnaround, reducing result waiting times from 48 hours to less than 12 hours. Large multispecialty hospitals perform an average of 50,000 blood screenings annually. The increasing number of surgical procedures, blood transfusions, and trauma cases continues to boost hospital-based demand for efficient and rapid blood testing technologies.

The Hospital segment is estimated to reach USD 2,211.53 million by 2034, accounting for 37.1% share, expanding at a CAGR of 7.3%, due to rising surgical procedures and internal transfusion testing requirements in healthcare settings.

Top 5 Major Dominant Countries in the Hospital Application:

• United States: USD 625.37 million by 2034, 28.3% share, CAGR 7.2%, led by growing hospital-based diagnostic capabilities.
• China: USD 455.42 million by 2034, 20.6% share, CAGR 7.4%, driven by increasing blood transfusion testing in large hospitals.
• Germany: USD 285.14 million by 2034, 12.9% share, CAGR 7.3%, supported by the expansion of advanced diagnostic infrastructure.
• Japan: USD 245.11 million by 2034, 11.1% share, CAGR 7.2%, due to higher testing standards for patient safety.
• India: USD 195.22 million by 2034, 8.8% share, CAGR 7.5%, driven by improvements in hospital-based blood screening services.

Blood Screening Market Regional Outlook

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

The Blood Screening Market demonstrates strong global distribution, with North America leading at 35%, Asia-Pacific following at 30%, Europe accounting for 25%, and the Middle East & Africa contributing 10%. Regional growth patterns align with healthcare spending, disease prevalence, and diagnostic infrastructure investments. Asia-Pacific’s expansion is driven by large population pools and government-backed healthcare programs. North America continues to dominate technologically with early adoption of molecular screening and automation, while Europe focuses on expanding its regulatory and public health frameworks to ensure universal access to safe blood.

NORTH AMERICA

North America maintains the largest market share of 35%, supported by advanced laboratory networks and high screening coverage rates. The U.S. conducts over 16 million blood donations annually, with 99.9% undergoing testing for HIV, HBV, HCV, and syphilis. Canada and Mexico together contribute 15% of the regional volume. North America’s Blood Screening Market Analysis also shows that rising demand for point-of-care testing devices—now adopted by 40% of emergency healthcare facilities—continues to shape market growth. The region’s robust regulatory ecosystem ensures safety and innovation in donor screening.

The North America Blood Screening market is expected to reach USD 2,180.45 million by 2034, representing 36.6% of global share, expanding at a CAGR of 7.2%, supported by advanced diagnostic infrastructure and mandatory blood testing regulations.

North America - Major Dominant Countries in the “Blood Screening Market”:

• United States: USD 1,675.14 million by 2034, 76.8% share, CAGR 7.2%, led by the adoption of molecular and immunoassay-based testing.
• Canada: USD 255.12 million by 2034, 11.7% share, CAGR 7.1%, driven by public health blood safety initiatives.
• Mexico: USD 125.14 million by 2034, 5.7% share, CAGR 7.3%, supported by improved healthcare facilities.
• Cuba: USD 70.18 million by 2034, 3.2% share, CAGR 7.0%, influenced by domestic healthcare modernization.
• Panama: USD 55.12 million by 2034, 2.6% share, CAGR 7.1%, driven by enhanced testing protocols in medical facilities.

EUROPE

Europe holds 25% of global Blood Screening Market Share, led by Germany, France, and the UK, which together account for 70% of regional demand. The region collects over 25 million blood donations annually, with 90% screened using advanced NAT and immunoassay systems. The European Union’s strict regulatory standards have increased laboratory automation rates by 40% since 2021. Investments in molecular testing infrastructure have improved accuracy by 25% and reduced contamination incidents by 15%. Ongoing research partnerships between healthcare agencies and manufacturers drive technological innovation across the region.

The Europe Blood Screening market is forecasted to achieve USD 1,685.42 million by 2034, capturing 28.3% share, expanding at a CAGR of 7.3%, owing to a strong focus on blood safety and technological integration in diagnostic testing.

Europe - Major Dominant Countries in the “Blood Screening Market”:

• Germany: USD 445.23 million by 2034, 26.4% share, CAGR 7.3%, supported by large-scale screening initiatives.
• United Kingdom: USD 365.11 million by 2034, 21.7% share, CAGR 7.2%, driven by national transfusion safety frameworks.
• France: USD 305.42 million by 2034, 18.1% share, CAGR 7.3%, boosted by automation in screening labs.
• Italy: USD 275.37 million by 2034, 16.3% share, CAGR 7.1%, fueled by growing healthcare modernization.
• Spain: USD 255.29 million by 2034, 15.1% share, CAGR 7.2%, supported by expanding blood donation networks.

ASIA-PACIFIC

Asia-Pacific dominates emerging market growth with 30% of the global Blood Screening Market. China, India, Japan, and South Korea contribute 80% of the regional volume. With over 40 million blood donations annually, demand for high-throughput testing systems is increasing rapidly. Technological adoption in the region is accelerating, with 35% of new facilities deploying AI-based automation platforms. Government-funded initiatives are improving rural testing infrastructure, ensuring access to safe blood across underserved populations. Asia-Pacific’s Blood Screening Market Outlook reflects strong innovation and scalability potential.

The Asia Blood Screening market is projected to reach USD 1,735.31 million by 2034, accounting for 29.1% of global share, growing at a CAGR of 7.6%, driven by rising healthcare investments and government programs to enhance blood safety.

Asia - Major Dominant Countries in the “Blood Screening Market”:

• China: USD 875.47 million by 2034, 50.4% share, CAGR 7.8%, supported by government-led donation and testing campaigns.
• Japan: USD 445.21 million by 2034, 25.6% share, CAGR 7.5%, led by innovation in molecular diagnostics.
• India: USD 305.14 million by 2034, 17.6% share, CAGR 7.9%, driven by rapid improvements in healthcare infrastructure.
• South Korea: USD 195.26 million by 2034, 11.2% share, CAGR 7.5%, fueled by advancements in automation technologies.
• Indonesia: USD 165.23 million by 2034, 9.5% share, CAGR 7.4%, driven by expansion in regional screening centers.

MIDDLE EAST & AFRICA

The Middle East & Africa account for 10% of the global market but display high growth potential. The UAE, Saudi Arabia, and South Africa collectively represent 60% of regional demand. Saudi Arabia performs approximately 2.5 million blood tests annually, with modernization efforts upgrading 40% of national screening centers. The African continent conducts around 12 million blood donations yearly, though only 70% undergo comprehensive screening. International health initiatives are improving this rate by 10% annually.

The Middle East and Africa Blood Screening market is estimated to reach USD 955.46 million by 2034, representing 16.0% share, with a CAGR of 7.1%, driven by growing healthcare awareness and expansion of diagnostic infrastructure.

Middle East and Africa - Major Dominant Countries in the “Blood Screening Market”:

• United Arab Emirates: USD 245.17 million by 2034, 25.6% share, CAGR 7.2%, supported by strong healthcare investment.
• Saudi Arabia: USD 225.19 million by 2034, 23.6% share, CAGR 7.1%, driven by improved hospital-based screening.
• South Africa: USD 185.24 million by 2034, 19.4% share, CAGR 7.0%, fueled by national blood safety programs.
• Egypt: USD 165.21 million by 2034, 17.3% share, CAGR 7.1%, influenced by healthcare modernization.
• Qatar: USD 134.65 million by 2034, 14.1% share, CAGR 7.0%, led by growing diagnostic automation adoption.

List of Top Blood Screening Companies

• Abbott Laboratories
• Abbott
• Apex Biotechnology Corp.
• Beckman Coulter (A Subsidiary of Danaher Corporation)
• Becton, Dickinson and Company
• Biomérieux
• Bio-Rad Laboratories, Inc.
• Hoffmann-La Roche
• Grifols
• Hem

Abbott Laboratories: Abbott holds approximately 20% of the global Blood Screening Market Share. The company supplies automated platforms such as the Alinity s and Architect series, performing over 100 million screenings annually worldwide.

1. Hoffmann-La Roche: Roche commands around 18% market share, serving over 120 countries. Its cobas series analyzers are installed in 3,000+ blood centers globally, enabling testing of up to 600 samples/hour.

Investment Analysis and Opportunities

Global investments in the Blood Screening Market surpassed $5 billion between 2023 and 2025, focusing on automation, molecular diagnostics, and decentralized screening solutions. Asia-Pacific accounted for 40% of these investments, particularly in China and India, where government initiatives supported modernization of over 200 blood centers. Venture funding for AI-driven screening startups increased by 30%, emphasizing predictive analytics and test optimization. North American companies are allocating over $1 billion annually toward new NAT platforms capable of multiplex detection. Opportunities exist in developing portable and point-of-care devices, with demand growing 18% yearly. Local reagent manufacturing initiatives in Africa and Latin America offer further investment potential, improving supply chain stability and reducing costs by 15–20%.

New Product Development

Recent innovations have reshaped the Blood Screening Industry. In 2024, over 40 new products were launched worldwide. Abbott introduced next-generation immunoassay platforms that process 500 tests/hour with enhanced digital traceability. Roche unveiled an AI-powered analyzer that minimizes manual review by 35%. Grifols developed molecular NAT kits capable of detecting six viruses simultaneously. Bio-Rad Laboratories launched reagents with 20% lower cross-reactivity, improving accuracy in multi-pathogen detection. Beckman Coulter introduced compact, modular analyzers designed for smaller laboratories with throughput exceeding 200 tests/hour. Manufacturers are increasingly focusing on eco-efficient designs and recyclable reagent packaging, with 30% of 2024’s new releases incorporating sustainable materials. Collectively, these innovations are shaping the Blood Screening Market Forecast toward faster, more automated, and environmentally responsible solutions.

Five Recent Developments

• Abbott Laboratories launched the Alinity s NAT analyzer, reducing screening time by 40% (2024).
• Roche expanded its cobas 6800/8800 platform installations across 25 new countries (2023).
• Grifols introduced a multiplex NAT assay detecting five pathogens simultaneously (2025).
• Bio-Rad Laboratories opened a new diagnostic reagent manufacturing plant in Asia (2024).
• Beckman Coulter released its high-throughput UniCel DxI analyzer series for blood banks (2023).

Report Coverage of Blood Screening Market

The Blood Screening Market Report provides comprehensive analysis across over 40 countries, covering product segmentation, regional performance, and competitive benchmarking. It evaluates the Blood Screening Market Size, Share, and Growth based on testing types, applications, and technological advancements. The report includes quantitative assessments of over 100 key products, 50+ laboratory automation systems, and 25 major manufacturers. Analytical coverage spans infectious disease testing, nucleic acid-based assays, and immunoassay platforms. The Blood Screening Market Outlook details future opportunities in automation, AI integration, and point-of-care screening. It also includes insights into evolving regulatory frameworks and global initiatives aimed at achieving 100% safe blood transfusion. With detailed Blood Screening Industry Analysis and strategic forecasting, this report equips stakeholders with actionable intelligence to identify emerging market opportunities and technological developments.

Blood Screening Market Report Coverage

REPORT COVERAGE	DETAILS
Market Size Value In	USD 3374.21 Million in 2026
Market Size Value By	USD 6397.44 Million by 2035
Growth Rate	CAGR of 7.4% from 2026 - 2035
Forecast Period	2026 - 2035
Base Year	2025
Historical Data Available	Yes
Regional Scope	Global
Segments Covered	By Type : Reagent Instrument By Application : Blood Bank Hospital
To Understand the Detailed Market Report Scope & Segmentation Download FREE Sample